Advanced Cell Diagnostics

Bio-Techne has also agreed to pay up to an additional $75 million if Advanced Cell Diagnostics achieves certain milestones.

The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.

The company will use the financing to accelerate its entry into the research and clinical diagnostics markets and to launch new technology platforms.

Flagship Bio is using ACD's RNAscope and customizing and optimizing the technology for use in CLIA clinical trials with "several large pharmaceutical clients."

Merrimack will use RNAscope to select patients with heregulin-positive, locally advanced metastatic NSCLC for a Phase II clinical trial for the drug candidate MM-121. 

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics announced today a preferred partnership agreement with Dundee, UK-based MicroMatrices to develop applications of its RNAscope technology.

NEW YORK (GenomeWeb) – Advanced Cell Dx today announced Edinburgh, Scotland-based CRO Aquila-Histoplex as the first accredited RNAscope Certified Service Provider in Europe.

NEW YORK (GenomeWeb) – A recent evaluation of FDA-approved molecular HPV screening assays from Roche, Hologic, and Qiagen has found that the three tests showed variations in which samples tested positive or negative.

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics today announced it has been awarded a two-year $1.4 million grant from the National Cancer Institute to develop and validate a diagnostic test for differentiating various B-cell non-Hodgkin lymphomas from benign lymphoproliferative diseases.

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics today announced the formation of a European subsidiary, to be operational next month.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.